Back to announcement
20251110_OMED_Laporan Informasi dan Fakta Material_31984145_lamp2.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 3
Page 1
INVESTOR BULLETIN COMPANY OVERVIEW
OPERATION UPDATE 9M 2025 PT Jayamas Medica Industri Tbk (OMED), established in
the early 2000s, has grown into a leading player in
November 07th 2025 Indonesia’s medical equipment and supplies industry.
OMED’s extensive product portfolio includes approximately
Share Price Data (per 06th of November 2025): 3,550 active SKUs, supported by a comprehensive
Ticker on IDX OMED distribution network that reaches 514 cities across all 34
provinces in Indonesia.
Last Closing Price (IDR): 195
COMPANY HIGHLIGHTS
Outstanding Shares: 27,058,850,000
• OMED posted resilient financial and operational
Market Cap (IDR Bn): 5,270
performance in 9M25. Revenue reached IDR 1.47 trillion,
an increase of 7.7% from IDR 1.36 trillion in 9M24. EBITDA
grew to IDR 318 billion with a 21.6% margin, while net
Shareholder Structure: profit increased to IDR 256 billion, reflecting a margin
PT Intisumber Hasilsempurna (%): 83.30 improvement to 17.4%.
Yacobus Jemmy Hartanto (%): 0.93 • Operationally, OMED recorded an 11.14% YoY
growth in total sales volume, reaching 2.02 billion
Siane Soetanto (%): 0.90 units in 9M25. The growth was driven by solid
Treasury Shares (%): 0.12 performances across key product segments such as
Diagnostic & Equipment (+67.11%), Biotech & Lab
Public (%): 14.75 (+23.39%), Wound Care (+13.78%), and Walking Aids &
Rehab (+11.68%). On pricing, the company maintained a
stable average selling price across most segments, with
Contact us: notable increases in Hospital Furniture (+22.95%) and
Walking Aids & Rehab (+6.58%).
Corporate Secretary & Investor Relation
• OMED is well-positioned to capture new export
Email:
opportunities as U.S. buyers increasingly diversify
corporate.secretary@onemed.co.id
ir@onemed.co.id away from China under the global China +1 strategy.
Leveraging Indonesia’s role as a trusted Southeast Asian
Website: manufacturing base, OMED continues to strengthen its U.S.
www.onemed.co.id market presence through quality, reliability, and expanding
export partnerships.
Company’s Presence Across Country
Sumatera 1 National Distribution
Center
Kalimantan Sulawesi
23 Branch offices and
warehouses
Maluku
Papua
11 Sales offices
Bali Lombok
Java Flores 28 Omnichannel
Stores
Page 2
OMED Maintains Solid YoY Growth Supported by Strong Private Performance
and Export Expansion
Revenue by Customer Profile Contribution
IDR Bn 9M25 9M24 YoY 9M25 9M24
Private 1,018 864 18% 69.2% 63.3%
Government 447 498 (10%) 30.4% 36.5%
Export 5.5 2.5 117% 0.4% 0.2%
Source: Company’s Internal Data, October 2025.
In 9M25, OMED recorded overall year-on-year (YoY) revenue growth, supported by strong performance in
the private segment, which grew 18% YoY.
The government segment started to pick up in 2H, yet declined 10% YoY due to budget cuts in 2025, while
the export segment rose sharply by 117% YoY, reflecting strong momentum in international sales.
Overall, OMED’s performance shows continued growth in private and export segments, partially offsetting the
decline in government sales.
Leveraging the C+1 (China +1) to Expand Global Reach
The global China +1 strategy presents a key opportunity for OMED to expand its export reach. As U.S.
companies reduce dependence on China to mitigate geopolitical and supply chain risks, Southeast Asia including
Indonesia has emerged as a strategic alternative manufacturing hub. OMED has successfully leveraged this
momentum by delivering high-quality products and reliable distribution that meet global standards.
Since beginning export discussions with the U.S. in 2021 and completing its first shipment in April 2022, OMED
has strengthened its position as a trusted Southeast Asian partner. Positive feedback from U.S. customers on
quality and reliability has led to new projects under validation and additional partnerships with U.S. based
companies to further expand export opportunities.
Page 3
Operational Highlights Unaudited
Production Price
(in thousand units) 9M 2024 9M 2025 YoY (in IDR) 9M 2024 9M 2025 YoY
Sales Volume Average Selling Price
Disposable & Consumables 1,128,113 1,246,690 10.5% Disposable & Consumables 601 580 (3.5%)
Wound Care 262,252 298,400 13.8% Wound Care 803 801 (0.2%)
Antiseptic & Dialysis Fluid 321,358 343,391 6.9% Antiseptic & Dialysis Fluid 472 475 0.7%
Diagnostic & Equipment 1,811 3,027 67.1% Diagnostic & Equipment 94,302 54,842 (41.8%)
Walking Aids & Rehab 1,192 1,331 11.7% Walking Aids & Rehab 50,896 54,244 6.6%
Biotech & Lab 105,509 130,189 23.4% Biotech & Lab 608 583 (4.1%)
Hospital Furniture 53 45 (15.1%) Hospital Furniture 533,070 655,388 22.9%
Total 1,820,289 2,023,073 11.1%
Source: Company’s Internal Data, October 2025.
Financial Highlights
Revenue (In Billion IDR) EBITDA (In Billion IDR) Net Profit (In Billion IDR)
1,886 7.7%
1,739 1,737
1,470
1,364
25.0%
21.6% 21.6% 16.8% 17.2% 17.4%
20.7% 21.4% 15.6%
14.9%
435 407 324
360 318 291 260 256
292 213
2022 2023 2024 9M24 9M25 2022 2023 2024 9M24 9M25 2022 2023 2024 9M24 9M25
Revenue Growth EBITDA EBITDA Margin Net Profit Net Profit Margin
Assets (In Billion IDR) Liabilities (In Billion IDR) Equity (In Billion IDR)
3,035
2,826 2,645
2,507 2,581 2,496
2,245
2,069
437 438
390
330
2022 2023 2024 9M25 2022 2023 2024 9M25 2022 2023 2024 9M25
Source: Company’s Financial Statement, October 2025.
Names mentioned 4 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Intisumber Hasilsempurna
p.1
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.